| Document |
Document Title |
|
WO/2023/040733A1 |
Disclosed in the present invention are a class of baicalein derivatives, and a preparation method therefor and the uses thereof. The structure of the baicalein derivative of the present invention is as represented by the following genera...
|
|
WO/2023/043946A2 |
The disclosure relates to a method of making at least one cannabinoid comprising contacting at least one berberine bridge enzyme like (BBE-like) oxidase with at least one substrate, wherein the substrate comprises a cannabinoid precursor...
|
|
WO/2023/035071A1 |
A cannabinoid-humic substances composition is provided. The cannabinoid-humic substances composition includes a cannabinoid and humic substances perforated by voids. The cannabinoid is complexed with humic substances and fixed in the voi...
|
|
WO/2023/034339A1 |
The present invention provides novel hydroxy and alkoxy coumarin compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial ...
|
|
WO/2023/032797A1 |
The present invention provides: an actinic ray sensitive or radiation sensitive resin composition containing a resin that undergoes decomposition through the action of an acid and gains a larger polarity, and a compound represented by a ...
|
|
WO/2023/034340A1 |
The present invention provides novel hydroxy and alkoxy coumarin compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial ...
|
|
WO/2023/034346A1 |
The present invention provides novel chromen-2-one compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunction.
|
|
WO/2023/024532A1 |
Disclosed in the present invention is a one-step method for preparing a C-N coupling product using nitroaromatic hydrocarbon and alkyl or phenylboronic acid. The method comprises: adding nitroaromatic hydrocarbon, alkyl or phenylboronic ...
|
|
WO/2023/028092A2 |
Provided are fluorinated analogs of MDMA, including fluorinated empathogens. In some embodiments, such compounds are monoamine releasers or inhibit monoamine transporters. In some aspects, features of the compounds provide stability, suc...
|
|
WO/2023/026884A1 |
To provide a curable composition that generates little outgas from an obtained cured product. The curable composition includes a radical polymerization initiator represented by formula 1 and a radical polymerizable compound. In formula 1...
|
|
WO/2023/028466A1 |
The present disclosure comprises hydrophilic linker compounds of Formula 1: and describes methods for their use in liquid phase synthesis. In Formula 1, "m" is 0 to 20, "n" is 1 to 50, and "Z" is a linker compound as described herein.
|
|
WO/2023/027948A1 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further rela...
|
|
WO/2023/026051A1 |
Methods for staining mitochondria are disclosed involving using a composition containing a cationic species of the formula: (I) wherein at least one of Y and Z is a substituted or unsubstituted azetidine group; X is selected from O, S, S...
|
|
WO/2023/021472A1 |
In one embodiment, the present invention describes a method for identifying an optimized natural medicine containing defined doses of active and contributing ingredients. In one embodiment, the method disclosed in the present invention d...
|
|
WO/2023/023044A1 |
The present disclosure provides esters of a retinoid and an alcohol selected from the group consisting of tocopherols and tert-butyl hydroquinone, such as esters of Formula (I). The present disclosure also provides compositions and kits ...
|
|
WO/2023/019821A1 |
The present invention provides an azaphilone polymer compound, and a preparation method therefor and the use thereof. According to the present invention, muyocopronlaterale is fermented and cultured, and a fermentation product is separat...
|
|
WO/2023/023112A1 |
Provided herein are methods for preparing 3-({[(4R)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro
-2H-1-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid and novel intermediate compounds for use in preparing histone demethylas...
|
|
WO/2023/017813A1 |
The present disclosure provides the methods for making 4-[4-cyano-2-({[(2'R,4S)-6-(isopropylcarbamoyl)-2,3-dihydros
piro[chromene-4,1'-cyclopropan]-2'-yl]carbonyl}amino)phenyl]
butanoic acid. The present disclosure also generally relates...
|
|
WO/2023/012691A1 |
The present disclosure relates to the transdermal administration of pharmaceutical agents, such as CBD, THC, psilocybin, psilocin, lysergic acid diethylamine (LSD), and/or ibogaine, and derivatives of these compounds, for the treatment a...
|
|
WO/2023/015268A1 |
Provided herein is the identification of the causal gene KR associated with THCV, THCVA, CBDV, CBDVA, CBGV, CBGVA, CBCV, or CBCVA production in Cannabis plants. Also included are isolated cells, nucleic acids, transgenic Cannabis plants;...
|
|
WO/2023/014362A1 |
A method for producing a medicinal food product includes the steps of homogenously mixing a first non-medicinal food base with at least one medicinal product to prepare a medicinal-infused food-based carrier, adding the carrier to a seco...
|
|
WO/2023/013549A1 |
A purpose of the present invention is to provide a xanthene compound which has high heat resistance and which, compared to conventional xanthene compounds, can block visible light ranging to longer wavelengths. This xanthene compound (...
|
|
WO/2023/008989A1 |
The present invention relates to a heterogeneous solid catalyst in the form of a film comprising: polystyrene, trimethyl phosphate and titanium dioxide, and also to the use thereof for 2-amino-4H-chromene synthesis. The catalyst film pro...
|
|
WO/2023/009955A1 |
Some variations provide a process of converting a cannabinoid into a purified cannabinoid derivative, comprising: providing a starting composition comprising a cannabinoid; providing a C9–C11 non-aromatic hydrocarbon solvent; introduci...
|
|
WO/2023/009629A1 |
The invention relates in one aspect to compounds, pharmaceutical compositions thereof, and methods using the same for selectively activating either all or a single isoform of Akt. Isoform selective-targeting is necessary for avoiding pat...
|
|
WO/2023/001268A1 |
The present invention relates to the technical field of drugs, and specifically relates to a chrysin derivative, and a preparation method therefor and the use thereof. The chrysin derivative has a structure as represented by formula I, a...
|
|
WO/2023/284775A1 |
Provided are a pyrazole derivative, and an intermediate thereof and a preparation method therefor. The method has the characteristics of a simple operation, high selectivity, low cost, environmental friendliness, etc., and is suitable fo...
|
|
WO/2023/284871A1 |
The present invention provides new crystal forms of the compound represented by formula I and a preparation method therefor. Specifically, the present invention provides new crystal forms A-D of the compound represented by formula I and ...
|
|
WO/2023/283977A1 |
The use of a preparation for inhibiting or blocking an interaction between FAAH and NLRP3. By using the preparation for inhibiting or blocking the interaction between FAAH and NLRP3, an NLRP3 protein is in an unstable state and is degrad...
|
|
WO/2023/284872A1 |
The present invention provides a new crystal form of a compound as represented by formula I and a preparation method therefor. Specifically, the present invention provides new crystal forms A-C of the compound as represented by formula I...
|
|
WO/2023/287249A1 |
The present invention provides a method for economically producing gossypetin, which can be used as a material in medicine, health care, cosmetics, health foods, and the like, with high purity and high yield through a four-step process.
|
|
WO/2023/281040A1 |
The present invention relates to novel bi-functionalized trans-cyclooctenes of formula (I). It also relates to conjugates, compositions, medical uses of such compounds, and methods for producing such compounds as well as conjugates of su...
|
|
WO/2023/282236A1 |
This rare earth complex is represented by a general formula (1). (In the formula, HC is a quinolinonato ligand and cumalinato ligand; L1 is a nitrogen-containing ligand, etc.; L2 is water, etc.; XL is a halide ion, etc.; M3+ is a trivale...
|
|
WO/2023/280817A1 |
Novel compounds derived from schweinfurthins G, E and F The present invention relates to novel compounds derived from schweinfurthins of formula (I): (I). The invention also relates to pharmaceutical compositions containing them and also...
|
|
WO/2023/278394A1 |
The present disclosure generally provides poly-alkali metal salts of flavanones, dihydrochalcones, and related polyphenolic compounds. In some aspects, the disclosure provides certain compositions that include such poly-alkali metal salt...
|
|
WO/2023/275324A1 |
The present invention relates to a process for preparing at least one schweinfurthin chosen from schweinfurthin G of formula (SW-G), schweinfurthin K of formula (SW-K) and schweinfurthin R of formula (SW-R), characterized in that it comp...
|
|
WO/2023/278719A1 |
Described herein are new derivatives of cannabichromene that are effective in treating or preventing pain in a subject. The new cannabichromene derivatives have improved bioavailability, which enhances their ability to treat or prevent p...
|
|
WO/2022/265925A1 |
A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition includin...
|
|
WO/2022/262456A1 |
The present invention relates to the technical field of Proanthocyanidin extraction, and in particular, to a method for extracting Proanthocyanidins from buckwheat hulls. The method specifically comprises: performing ultrasonic extractio...
|
|
WO/2022/261752A1 |
There is currently no effective cure or treatment for neurodegenerative diseases associated with progranulin (PGRN) deficiency, such as frontotemporal dementia (FTD). FTD is a fast-progressing disease, with affected patients usually dyin...
|
|
WO/2022/258792A1 |
The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever...
|
|
WO/2022/260167A1 |
A photochromic compound represented by general formula 1. In general formula 1, R1 and R2 bond with one another and form a ring structure along with a carbon atom at the 13 position of an indeno-fused naphthopyran, R3 to R6 each independ...
|
|
WO/2022/260240A1 |
The present specification provides a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2022/261401A1 |
Solid state forms of Abexinostat salts and of Abexinostat tosylate : p-toluenesulfonic acid monohydrate complex, processes for preparation thereof, pharmaceutical compositions and uses thereof are disclosed.
|
|
WO/2022/255416A1 |
The purpose of the present invention is to provide: a method for producing a catechin conjugate with high efficiency by a semi-synthesis process; and an intermediate for the production of the catechin conjugate. Provided is a method fo...
|
|
WO/2022/254465A1 |
The present invention relates to substituted benzophenones of structural Formula I employed as small molecule inhibitor for controlling obesity. The present invention further relates to screening of small molecule inhibitors against p300...
|
|
WO/2022/255765A1 |
The present invention provides a fluorine-substituted flavonoid derivative compound, and a pharmaceutical composition for preventing or treating allergic diseases, comprising same. A fluorine-substituted flavonoid derivative compound of ...
|
|
WO/2022/255417A1 |
Provided are: a method for efficiently producing a catechin conjugate by means of a semi-synthetic method; and a production intermediate of said catechin conjugate. The present invention provides a method for producing an allylated cat...
|
|
WO/2022/256480A1 |
The present disclosure provides a method of preparing certain 3,4-dihydro-4-aryl coumarin derivatives. Cinnamic acid, or a certain derivative thereof, may react with phenol, or a certain derivative thereof (e.g., resorcinol), with remova...
|
|
WO/2022/247097A1 |
A method for separating active ingredients from Siraitia grosvenorii flowers, comprising: S1, extracting Siraitia grosvenorii flowers with water vapor to obtain wet flowers and a first extracting solution; S2, extracting the wet flowers ...
|
